Open access · CC-BY
via OpenAlex
MYDGF as a telomerase activator and therapeutic target for osteoarthritis
Yijun He, Chujun Li, Kexin Chen, Xining Wang, Shengxin Xu, Zhifen Zhou, Li Yin, Jialu Zheng, Yifan Wu, Wenbin Ma, Zhou Songyang, Yan Y. Huang
Advanced Biotechnology · 2026
Abstract
Osteoarthritis (OA) involves progressive cartilage breakdown. This is driven by impaired chondrocyte function and an imbalance in the extracellular matrix homeostasis. However, the key upstream regulators that maintain healthy chondrocytes are still not fully known. Here, we report that myeloid-derived growth factor (MYDGF) is a novel regulator of telomerase activity and is critical for cartilage health. Using a genome-wide CRISPR-Cas9 screen with a TERT reporter system, MYDGF was identified as a strong positive regulator of telomerase. Functional studies confirmed that MYDGF positively regulates TERT expression and telomerase activity in both HeLa and ATDC5 cells. In a mouse surgical destabilization of the medial meniscus (DMM) OA model, MYDGF knockout (KO) mice exhibited more severe cartilage damage. Conversely, delivering MYDGF into the knee joint using AAV virus partially alleviated cartilage injury. Transcriptome profiling revealed that MYDGF-deficient chondrocytes exhibit downregulated key pathways involved in matrix building and upregulated inflammatory signals, indicating a shift in cell state. In summary, our work establishes MYDGF as a key upstream factor for both telomerase and cartilage matrix homeostasis remodeling. It connects telomerase function to chondrocyte health. These findings also highlight MYDGF as a promising new target for treating osteoarthritis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s44307-026-00119-6
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
He, Y., Li, C., Chen, K., Wang, X., Xu, S., Zhou, Z., Yin, L., Zheng, J., Wu, Y., Ma, W., Songyang, Z., & Huang, Y.Y. (2026). MYDGF as a telomerase activator and therapeutic target for osteoarthritis. <em>Advanced Biotechnology</em>. https://doi.org/10.1007/s44307-026-00119-6
Vancouver
He Y, Li C, Chen K, Wang X, Xu S, Zhou Z, et al. MYDGF as a telomerase activator and therapeutic target for osteoarthritis. Advanced Biotechnology. 2026. doi:10.1007/s44307-026-00119-6.
BibTeX
@article{yijun2026MYDGFa,
title = {MYDGF as a telomerase activator and therapeutic target for osteoarthritis},
author = {Yijun He and Chujun Li and Kexin Chen and Xining Wang and Shengxin Xu and Zhifen Zhou and Li Yin and Jialu Zheng and Yifan Wu and Wenbin Ma and Zhou Songyang and Yan Y. Huang},
journal = {Advanced Biotechnology},
year = {2026},
doi = {10.1007/s44307-026-00119-6},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Advanced biotechnology 2026
Open access · OA
MYDGF as a telomerase activator and therapeutic target for osteoarthritis.
Clinical Cancer Research 2009
Open access · OA
Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase
Journal of Neuroscience 2011
Open access · CC-BY
Hippocampal Telomerase Is Involved in the Modulation of Depressive Behaviors
2016
Preprint · OA
Iron and not mTOR is the primary driver of aging
GeroScience 2026
Open access · CC-BY
Circulating factors induced by time-restricted eating drive metabolic reprogramming in endothelial cells
Current Cancer Drug Targets 2022
Preprint · OA